Effectiveness of a low dose @entity10551 to improve sexual function in postmenopausal XXXX .

@entity1 @entity172 @entity251 @entity458 @entity10551
BACKGROUND: Adding @entity251 to hormonal therapy could improve sexual function and general well-being among @entity1 during climacteric. We evaluated the effectiveness of @entity10551 on sexual function in postmenopausal @entity1 utilizing the standardized questionnaire @entity458 score. METHODS: Postmenopausal @entity1 with sexual complaints and @entity458 ( @entity458 )  <= 26.5 were enrolled in to this randomized, double-blinded, placebo-controlled trial. @entity1 were randomly assigned to 8-week treatment with either oral @entity10551 40 mg or placebo twice weekly with daily oral @entity172 . The @entity458 scores before and after treatment were compared to assess any improvement of sexual function. RESULTS: Seventy @entity1 were recruited of which each group had 35 @entity1 . The baseline characteristics and baseline @entity458 scores were comparable between both groups. After 8 weeks of treatment, the @entity458 scores significantly improved in both groups when compared to the baseline but the @entity458 scores from the @entity251 group were significantly higher than in the placebo group post-treatment (28.6    3.6, 25.3    6.7, respectively, p = 0.04). There was no difference in adverse effect between the two groups CONCLUSIONS: The twice weekly addition of @entity10551 to daily oral @entity172 was associated with a significant improvement in sexual function among postmenopausal @entity1 than the use of the @entity172 alone. TRIAL REGISTRATION: ClinicalTrials.gov Identifier NCT01724658 (February 17, 2012).
